3 hours ago
- Long-acting amylin analogs are a promising new class of injectable therapy for diabetes and obesity, potentially becoming a first-choice treatment for many patients.
- Amylin is a pancreatic hormone that promotes satiety, slows gastric emptying, reduces glucagon secretion, and prevents the decrease in energy expenditure during weight loss.
- Long-acting amylins offer better gastrointestinal tolerability compared to GLP-1 receptor agonists like semaglutide and tirzepatide, making them an alternative or add-on to incretin therapies.
- Amylin may positively affect bone health by promoting bone formation and inhibiting bone resorption through activation of calcitonin receptors.